Access site complications after peripheral vascular interventions: Incidence, predictors, and outcomes

Circulation: Cardiovascular Interventions

Volumn 7, Issue 6, 2014, Pages 821-828

  Ortiz, Daniel ^a   Jahangir, Arshad ^b   Singh, Maharaj ^a   Allaqaband, Suhail ^a   Bajwa, Tanvir K ^a   Mewissen, Mark W ^c  

^a AURORA SINAI MEDICAL CENTER   (United States)

^b AURORA HEALTH CARE   (United States)

^c ST LUKE S MEDICAL CENTER   (United States)

Author keywords

Aneurysm; False; Hematoma; Mortality

Indexed keywords

THROMBIN; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ACCESS SITE HEMATOMA; ACCESS SITE PSEUDOANEURYSM; AGE; AGED; ARTERY DISSECTION; ARTICLE; BLOOD TRANSFUSION; CARDIOVASCULAR MORTALITY; CAUCASIAN; FALSE ANEURYSM; FEMALE; FLUOROSCOPY; HEMATOMA; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; IMMOBILITY; INCIDENCE; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR INTERVENTION; PRIORITY JOURNAL; REHABILITATION CARE; RETROSPECTIVE STUDY; RISK FACTOR; SEX; TREATMENT INDICATION; VASCULAR CLOSURE DEVICE; ADVERSE EFFECTS; ANEURYSM, FALSE; CATHETERIZATION; CLINICAL TRIAL; DEVICES; LENGTH OF STAY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANEURYSM, FALSE; ANTICOAGULANTS; BLOOD TRANSFUSION; CATHETERIZATION, PERIPHERAL; FEMALE; FIBRINOLYTIC AGENTS; HEMATOMA; HUMANS; INCIDENCE; LENGTH OF STAY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925877452     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.114.001306     Document Type: Article

References (33)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER III, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2014 update: A report from the American Heart Association. Circulation. 2014;129: E28-e292.
2. White CJ, Gray WA. Endovascular therapies for peripheral arterial disease: An evidence-based review. Circulation. 2007;116: 2203-2215.
3. Anderson PL, Gelijns A, Moskowitz A, Arons R, Gupta L, Weinberg A, Faries PL, Nowygrod R, Kent KC. Understanding trends in inpatient surgical volume: Vascular interventions, 1980-2000. J Vasc Surg. 2004;39: 1200-1208.
4. Shammas NW, Shammas GA, Jerin M, Dippel EJ, Shammas AN. Inhospital safety and effectiveness of bivalirudin in percutaneous peripheral interventions: Data from a real-world registry. J Endovasc Ther. 2010;17: 31-36.
5. Sheikh IR, Ahmed SH, Mori N, Gupta A, Mewissen M, Allaqaband S, Bajwa T. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in percutaneous peripheral intervention: A single-center experience. JACC Cardiovasc Interv. 2009;2: 871-876.
6. Walker S, Beasley C, Reeves M. A retrospective study on the use of heparin for peripheral vascular intervention. Perspect Vasc Surg Endovasc Ther. 2012;24: 63-69.
7. Krajcer Z, Howell MH. Update on endovascular treatment of peripheral vascular disease: New tools, techniques, and indications. Tex Heart Inst J. 2000;27: 369-385.
8. Kasapis C, Gurm HS, Chetcuti SJ, Munir K, Luciano A, Smith D, Aronow HD, Kassab EH, Knox MF, Moscucci M, Share D, Grossman PM. Defining the optimal degree of heparin anticoagulation for peripheral vascular interventions: Insight from a large, regional, multicenter registry. Circ Cardiovasc Interv. 2010;3: 593-601.
9. Shammas NW. Complications in peripheral vascular interventions: Emerging role of direct thrombin inhibitors. J Vasc Interv Radiol. 2005;16(2 pt 1): 165-171.
10. Cronenwett JL, Kraiss LW, Cambria RP. The Society for Vascular Surgery Vascular Quality Initiative. J Vasc Surg. 2012;55: 1529-1537.
11. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11: 1-11.
12. Mehta SK, Frutkin AD, Lindsey JB, House JA, Spertus JA, Rao SV, Ou FS, Roe MT, Peterson ED, Marso SP; National Cardiovascular Data Registry. Bleeding in patients undergoing percutaneous coronary intervention: The development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Interv. 2009;2: 222-229.
13. Feit F, Voeltz MD, Attubato MJ, Lincoff AM, Chew DP, Bittl JA, Topol EJ, Manoukian SV. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol. 2007;100: 1364-1369.
14. Vavalle JP, Rao SV. Impact of bleeding complications on outcomes after percutaneous coronary interventions. Interv Cardiol. 2009;1: 51-62.
15. Yatskar L, Selzer F, Feit F, Cohen HA, Jacobs AK, Williams DO, Slater J. Access site hematoma requiring blood transfusion predicts mortality in patients undergoing percutaneous coronary intervention: Data from the National Heart, Lung, and Blood Institute Dynamic Registry. Catheter Cardiovasc Interv. 2007;69: 961-966.
16. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, Dangas GD, Lincoff AM, White HD, Moses JW, King SB III, Ohman EM, Stone GW. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: An analysis from the ACUITY Trial. J Am Coll Cardiol. 2007;49: 1362-1368.
17. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, Pinnow EE, Kent KM, Pichard AD, Satler LF, Weissman NJ, Lindsay J, Fuchs S. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003;92: 930-935.
18. Fuchs S, Kornowski R, Teplitsky I, Brosh D, Lev E, Vaknin-Assa H, Ben-Dor I, Iakobishvili Z, Rechavia E, Battler A, Assali A. Major bleeding complicating contemporary primary percutaneous coronary interventionsincidence, predictors, and prognostic implications. Cardiovasc Revasc Med. 2009;10: 88-93.
19. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114: 774-782.
20. Sulzbach-Hoke LM, Ratcliffe SJ, Kimmel SE, Kolansky DM, Polomano R. Predictors of complications following sheath removal with percutaneous coronary intervention. J Cardiovasc Nurs. 2010;25: E1-E8.
21. Ayhan E, Isik T, Uyarel H, Ergelen R, Cicek G, Ghannadian B, Halil Tanboga I, Ergelen M, Eren M. Femoral pseudoaneurysm in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: Incidence, clinical course and risk factors. Int Angiol. 2012;31: 579-585.
22. Badr S, Kitabata H, Torguson R, Chen F, Suddath WO, Satler LF, Pichard AD, Waksman R, Bernardo NL. Incidence and correlates in the development of iatrogenic femoral pseudoaneurysm after percutaneous coronary interventions. J Interv Cardiol. 2014;27: 212-216.
23. Delhaye C, Wakabayashi K, Maluenda G, Belle L, Ben-Dor I, Gonzalez MA, Gaglia MA Jr, Torguson R, Xue Z, Suddath WO, Satler LF, Kent KM, Lindsay J, Pichard AD, Waksman R. Body mass index and bleeding complications after percutaneous coronary intervention: Does bivalirudin make a difference? Am Heart J. 2010;159: 1139-1146.
24. Manoukian SV, Voeltz MD, Eikelboom J. Bleeding complications in acute coronary syndromes and percutaneous coronary intervention: Predictors, prognostic significance, and paradigms for reducing risk. Clin Cardiol. 2007;30(10 suppl 2): II24-II34.
25. Marso SP, Amin AP, House JA, Kennedy KF, Spertus JA, Rao SV, Cohen DJ, Messenger JC, Rumsfeld JS; National Cardiovascular Data Registry. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA. 2010;303: 2156-2164.
26. Gurm HS, Hosman C, Share D, Moscucci M, Hansen BB; Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Comparative safety of vascular closure devices and manual closure among patients having percutaneous coronary intervention. Ann Intern Med. 2013;159: 660-666.
27. Sanborn TA, Ebrahimi R, Manoukian SV, McLaurin BT, Cox DA, Feit F, Hamon M, Mehran R, Stone GW. Impact of femoral vascular closure devices and antithrombotic therapy on access site bleeding in acute coronary syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Circ Cardiovasc Interv. 2010;3: 57-62.
28. Wayangankar SA, Abu-Fadel MS, Aronow HD, Kennedy KF, Gupta R, Yeh RW, Gray WA, Rosenfield K, Hennebry TA. Hemorrhagic and ischemic outcomes after bivalirudin versus unfractionated heparin during carotid artery stenting: A propensity score analysis from the NCDR. Circ Cardiovasc Interv. 2013;6: 131-138.
29. Spencer FA, Moscucci M, Granger CB, Gore JM, Goldberg RJ, Steg PG, Goodman SG, Budaj A, FitzGerald G, Fox KA; GRACE Investigators. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation. 2007;116: 2793-2801.
30. Lorenzoni R, Roffi M. Transradial access for peripheral and cerebrovascular interventions. J Invasive Cardiol. 2013;25: 529-536.
31. Baklanov DV, Kim S, Marso SP, Subherwal S, Rao SV. Comparison of bivalirudin and radial access across a spectrum of preprocedural risk of bleeding in percutaneous coronary intervention: Analysis from the national cardiovascular data registry. Circ Cardiovasc Interv. 2013;6: 347-353.
32. Kiemeneij F, Laarman GJ, Odekerken D, Slagboom T, van der Wieken R. A randomized comparison of percutaneous transluminal coronary angioplasty by the radial, brachial and femoral approaches: The access study. J Am Coll Cardiol. 1997;29: 1269-1275.
33. Hillegass WB, Brott BC, Chapman GD, Phillips HR, Stack RS, Tcheng JE, Califf RM. Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications. Am Heart J. 2002;144: 501-507.